GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

nerandomilast   Click here for help

GtoPdb Ligand ID: 12518

Synonyms: BI 1015550 | BI-1015550 | BI1015550
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: BI-1015550 is a PDE4B inhibitor [1]. It is an orally bioavailable compound, and clinical lead for the treatment of idiopathic pulmonary fibrosis. This compound was developed as a possible successor anti-fibrotic mechanism to nintedanib (Ofev) for the treatment of interstitial lung diseases [2,4]. BI-1015550's chemical structure was matched to the INN nerandomilast from proposed INN list 129 (August 2023).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

nerandomilast is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 121.22
Molecular weight 448.97
XLogP -0.93
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1CC(C1)(CO)NC2=C3C(=NC(=N2)N4CCC(CC4)C5=NC=C(C=N5)Cl)CC[S@]3=O
Isomeric SMILES OCC1(CCC1)NC2=NC(=NC3=C2[S@](=O)CC3)N4CCC(CC4)C5=NC=C(Cl)C=N5
InChI InChI=1S/C20H25ClN6O2S/c21-14-10-22-17(23-11-14)13-2-7-27(8-3-13)19-24-15-4-9-30(29)16(15)18(25-19)26-20(12-28)5-1-6-20/h10-11,13,28H,1-9,12H2,(H,24,25,26)/t30-/m1/s1
InChI Key UHYCLWAANUGUMN-SSEXGKCCSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
BI-1015550 has reached phase 3 clinical trial to determine efficacy in interstitial lung diseases such as idiopathic pulmonary fibrosis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05321069 A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) Phase 3 Interventional Boehringer Ingelheim Results from this study (FIBRONEER-IPF trial) show that nerandomilast significantly reduces decline in forced vital capacity (FVC) compared to placebo in patients with IPF at week 52, including in patients on background antifibrotic therapy. 5
NCT05321082 A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Phase 3 Interventional Boehringer Ingelheim The FIBRONEER-ILD trial: Nerandomilast met its primary endpoint in this study (absolute change from baseline in forced vital capacity at Week 52) in patients with progressive pulmonary fibrosis. The results indicate that nerandomilast treatment slows disease progression rather than stopping it, with a modest effect on lung function. 3